Correlation and predictive value of pathological complete response and ultrasound characteristic parameters in neoadjuvant chemotherapy for breast

Table 1 Comparison of ultrasound characteristics between pathological complete response group and non-pathological complete response group

Ultrasonic feature	PCR group, n = 59	Non PCR group, n = 59	χ2	P value
Edge of lesion			1.374	0.241
Burr	41 (69.49)	72 (60.50)
Smooth	18 (30.51)	47 (39.50)
Calcification lesion			1.532	0.216
Yes	27 (45.76)	43 (36.13)
No	32 (54.24)	76 (63.87)
Peripheral echo halo			2.053	0.152
High and low echo dizziness	32 (54.24)	51 (42.86)
No	27 (45.76)	68 (57.14)
Posterior echo			6.767	0.009
Attenuation	38 (64.41)	52 (43.7)
Unchanged	21 (35.59)	67 (56.3)
Tumor morphology			1.464	0.226
Quasi-circular object	11 (18.64)	32 (26.89)
Irregular	48 (81.36)	87 (73.11)
Lesion diameter			6.769	0.006
≥ 2.0 cm	36 (61.02)	48 (40.34)
< 2.0 cm	23 (38.98)	71 (59.66)
Alder blood flow grading			4.448	0.035
≥ II stage	41 (69.49)	63 (52.94)
< II stage	18 (30.51)	56 (47.06)

Data are n (%). PCR: Pathological complete response.

Table 2 The value of ultrasound features in predicting the efficacy of neoadjuvant chemotherapy in breast cancer

Ultrasonic feature	Sensitivity	Specificity	Missed diagnosis	Misdiagnosis rate	AUC value
Posterior echo	64.41	56.30	35.59	43.70	0.604
Lesion diameter	61.02	59.66	38.98	40.34	0.603
Alder blood flow grading	69.49	47.06	30.51	52.94	0.583

Data are %. AUC: Area under the curve.

Table 3 Comparison of general data and pathological data between pathological complete response group and non-pathological complete response group

Index	PCR group, n = 59	Non PCR group, n = 119	t/χ2	P value
Age in year	44.8 ± 5.2	46.1 ± 6.4	-1.354	0.178
BMI in kg/m2	22.62 ± 1.33	22.85 ± 1.41	-1.044	0.298
Menstrual status			1.447	0.229
Menopause	16 (27.12)	43 (36.13)
Premenopausal	43 (72.88)	76 (63.87)
Affected side distribution			0.634	0.426
Left	27 (45.76)	62 (52.1)
Right	32 (54.24)	57 (47.9)
Pathological type			0.565	0.452
Infiltrating ductal carcinoma	48 (81.36)	102 (85.71)
Other types	11 (18.64)	17 (14.29)
Pathological staging			4.893	0.027
II stage	18 (30.51)	57 (47.9)
III stage	41 (69.49)	62 (52.1)
Lymph node metastasis			3.898	0.048
Yes	11 (18.64)	39 (32.77)
No	48 (81.36)	80 (67.23)
Vascular invasion			8.128	0.004
Yes	34 (57.63)	93 (78.15)
No	25 (42.37)	26 (21.85)
Ki-67			5.704	0.017
Positive	22 (37.29)	67 (56.3)
Negative	37 (62.71)	52 (43.7)
HER-2			2.706	0.100
Positive	33 (55.93)	51 (42.86)
Negative	26 (44.07)	68 (57.14)
ER			3.497	0.061
Positive	21 (35.59)	60 (50.42)
Negative	38 (64.41)	59 (49.58)

Data are n (%). BMI: Body mass index; PCR: Pathological complete response.

Table 4 Multivariate analysis results

Index	β	SE	Walds	P value	OR	95%CI
Posterior echo	0.511	0.221	5.346	0.025	1.667	1.081	2.571
Lesion diameter	0.481	0.24	4.017	0.048	1.618	1.011	2.589
Alder blood flow grading	0.602	0.251	5.752	0.003	1.826	1.116	2.986
Pathological staging	0.648	0.238	7.413	0.000	1.912	1.199	3.048
Lymph node metastasis	0.392	0.203	3.729	0.073	1.480	0.994	2.203
Vascular invasion	0.711	0.251	8.024	0.000	2.036	1.245	3.330
Ki-67	0.641	0.227	7.974	0.000	1.898	1.217	2.962
Constant term	1.403	0.784	3.202	0.096	4.067	0.875	18.909